Amylin is a pancreatic β-cell hormone that produces effects in several different organ
systems. Here, we review the literature in rodents and in humans on amylin research since …

Aims To evaluate current evidence of glucagon-like peptide-1 receptor agonists (GLP-1RAs)
on blood pressure, heart rate, and hypertension in patients with type 2 diabetes. Methods …

Purpose The goal of this study was to assess the effect of glucagon-like peptide-1 receptor
agonists (GLP-1 RAs) on lipid profiles in patients with type 2 diabetes. Methods The …

Incretin‐based therapies, the most recent therapeutic options for type 2 diabetes mellitus
(T2DM) management, can modify various elements of the disease, including hypersecretion …

Antagonizing glucagon action represents an attractive therapeutic option for reducing
hepatic glucose production in settings of hyperglycemia where glucagon excess plays a key …

Glucose-dependent insulinotropic polypeptide (GIP) is glucagonotropic, and glucagon-like
peptide-1 (GLP-1) is glucagonostatic. We studied the effects of GIP and GLP-1 on glucagon …

In 1902 William Bayliss and Ernest Starling discovered secretin and it was the beginning of
general endocrinology as well as, endocrinology of gastrointestinal tract. Ernest Starling was …

Cerebral edema is a common complication following moderate and severe traumatic brain
injury (TBI), and a significant risk factor for development of neuronal death and deterioration …

Objective Roux‐en‐Y gastric bypass surgery (GB) is characterized by accentuated but short‐
lived postprandial elevations of blood glucose and insulin. This profile has been attributed to …

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are increasingly used in patients
with type 2 diabetes. However, the effect on abdominal obesity has not yet been confirmed …